IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
1.410
-0.090 (-6.00%)
Feb 21, 2025, 4:00 PM EST - Market closed
IceCure Medical Employees
As of December 31, 2023, IceCure Medical had 77 total employees, including 71 full-time and 6 part-time employees. The number of employees increased by 5 or 6.94% compared to the previous year.
Employees
77
Change (1Y)
5
Growth (1Y)
6.94%
Revenue / Employee
$47,675
Profits / Employee
-$179,662
Market Cap
79.76M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 77 | 5 | 6.94% |
Dec 31, 2022 | 72 | 8 | 12.50% |
Dec 31, 2021 | 64 | 17 | 36.17% |
Dec 31, 2020 | 47 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
ICCM News
- 18 days ago - IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision - PRNewsWire
- 26 days ago - IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China - PRNewsWire
- 5 weeks ago - IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America - PRNewsWire
- 6 weeks ago - IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule - PRNewsWire
- 7 weeks ago - European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology - PRNewsWire
- 2 months ago - Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting - PRNewsWire
- 3 months ago - IceCure Medical Ltd (ICCM) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation - PRNewsWire